Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Infliximab
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Flixabi 100mg pdr for concentrate for inf vials
1001030T0BEAAAA
|
Flixabi | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Inflectra 100mg pdr for concentrate for inf vials
1001030T0BDAAAA
|
Inflectra | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Infliximab 100mg powder for solution for infusion vials
1001030T0AAAAAA
|
Infliximab | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Infliximab 120mg/1ml inj pre-filled disposable devices
1001030T0AAABAB
|
Infliximab | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Infliximab 120mg/1ml inj pre-filled syringes
1001030T0AAACAC
|
Infliximab | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remicade 100mg pdr for concentrate for inf vials
1001030T0BBAAAA
|
Remicade | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remsima 100mg pdr for concentrate for inf vials
1001030T0BCAAAA
|
Remsima | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remsima 120mg/1ml solution for injection pre-filled pens
1001030T0BCABAB
|
Remsima | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remsima 120mg/1ml solution for injection pre-filled syringes
1001030T0BCACAC
|
Remsima | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Zessly 100mg pdr for concentrate for inf vials
1001030T0BFAAAA
|
Zessly | Infliximab | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.